TargImmune Therapeutics gets acquired

This strategic acquisition significantly enhances iOncologi’s capabilities in developing cutting-edge immunotherapies for solid tumors.

TargImmune Therapeutics is developing targeted immunotherapy solutions designed to enhance anti-tumor immune responses. Ta:RNA,  the company’s proprietary, first-in-class platform harnesses the body’s own immune system and powerful antiviral defence responses to selectively target and destroy cancer cells. Its immunomodulating therapeutics are designed to be delivered systemically, allowing them to reach distant metastases, which are the leading cause of cancer death.

TargImmune’s lead drug candidate, TAR001, targets epidermal growth factor receptors (EGFR). EGFR overexpression is prevalent in a significant proportion of solid cancers and is often associated with more aggressive disease. As TargImmune’s lead targeted apoptosis and immune modulator (TAIM) therapy, TAR001 has the potential to be applied to a wide range of cancers and change the lives of a large number of cancer patients.

The company has now joined the iOncologi family to develop novel immunotherapies for the treatment of solid tumor cancers. As part of the acquisition deal, the companies executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune’s shares, warrants, and options.

Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure ensures the seamless continuation of TargImmune’s research into novel tumor-targeted RNA therapies while benefiting from iOncologi’s expanded resources and strategic vision.

“This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumors,” said Dr. Edgardo Rodriguez-Lebron, iOncologi’s recently appointed CEO. “TargImmune’s pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options.”

Source: startupticker.ch